Compounded four-peptide recovery/skin blend (BPC-157 + GHK-Cu + TB-500 + KPV)
KLOW is an informal combination of four peptides sold together to target tissue repair, recovery, skin health, and inflammation.
| Class / type | Compounded four-peptide recovery/skin blend (BPC-157 + GHK-Cu + TB-500 + KPV) |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
Each component works on a different repair pathway: BPC-157 for soft-tissue and gut healing and angiogenesis, TB-500 for cell migration and wound closure, GHK-Cu for collagen/tissue remodeling, and KPV for calming inflammation. The blend itself is not studied as a unit.
Used in peptide communities for injury recovery, soft-tissue and joint healing, skin/wound repair, and inflammation control; no published human trial exists for the combined blend.
Anecdotal broad recovery, skin, and anti-inflammatory benefits, with users citing the convenience of a single combined product covering multiple repair pathways.
Not FDA-approved and untested as a combination; it inherits every component's risks, including the theoretical tumor/angiogenesis concern from BPC-157 and TB-500 (their healing effects grow new blood vessels, which a tumor could also exploit). Unregulated material adds purity, sterility, and dosing risks.
Users often report strong subjective recovery and skin benefits and view it as a convenient all-in-one stack, but sentiment is enthusiast-driven and not backed by human trials of the blend.
NOT FDA-approved. None of the four components is FDA-approved for human use. Three of them (BPC-157, TB-500 and KPV) were recommended for 503A compounding by an FDA advisory panel in July 2026, but that vote is advisory and not yet final. The blend is treated as research-use-only.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.